首页> 外文期刊>Clinical Medicine Insights: Therapeutics >A Review of Treatments That Improve Cystic Fibrosis Transmembrane Conductance Regulator Function
【24h】

A Review of Treatments That Improve Cystic Fibrosis Transmembrane Conductance Regulator Function

机译:改善囊性纤维化跨膜电导调节器功能的治疗方法的综述

获取原文
           

摘要

Cystic fibrosis (CF) is a common life-limiting genetic condition caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR protein is present in many epithelial cells in the body, and CF is characterised by suppurative lung disease, exocrine pancreatic insufficiency, and elevated sweat chloride. Traditionally, treatment of CF has involved managing the complications of defective CFTR function, such as airway clearance techniques for impaired lung mucociliary clearance and pancreatic enzyme replacement for pancreatic insufficiency. More recently, treatments have been developed which improve CFTR function. The aim of this article is to summarise the evidence surrounding treatments that improve CFTR function and their implications for clinical practice.
机译:囊性纤维化(CF)是一种常见的限制生命的遗传病,由囊性纤维化跨膜电导调节剂(CFTR)基因突变引起。 CFTR蛋白存在于体内的许多上皮细胞中,CF的特征是化脓性肺部疾病,外分泌胰腺功能不全和汗液氯化物升高。传统上,CF的治疗涉及处理CFTR功能缺陷的并发症,例如用于清除肺粘膜纤毛清除功能的气道清除技术和用于胰腺功能不全的胰腺酶替代。最近,已经开发出改善CFTR功能的治疗方法。本文的目的是总结围绕改善CFTR功能的治疗的证据及其对临床实践的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号